Sanjivani Paranteral Ltd — Updates, 27-05-2025: Company Update

Date: 27th February, 2025

To,

Department of Corporate Services

BSE Limited,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

Scrip Code: 531569

Sub: Investor Presentation for the Quarter and Year ended March 31, 2025.

Dear Sir/ Madam,

Please find enclosed herewith Investor Presentation of Sanjivani Paranteral

Limited highlighting the performance of the Company during the Quarter and

Year ended March 31, 2025.

Kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam

Company Secretary Cum Compliance Officer

----------------Page (0) Break----------------

Investor Presentation Q4 & FY25

Sanjivani

Paranteral Ltd

s a n j i v a n i . c o . i n

----------------Page (1) Break----------------

s a n j i v a n i . c o . i n

TABLE OF CONTENT

04

Market Overview

22

Global Footprint

07

About The Company

24

Product Portfolio

13

Manufacurting Plant

28

Financials

16

CDMO Key Clients

36

Stock Information

18

Company’s Segment &

Revenue Mix

----------------Page (2) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Key Financial Highlights

3

Rs. In Mn.

701.0

Revenue from Operations

(up 28.8% Y-o-Y)

81.0

PAT

(up by 31.4% Y-o-Y)

EBIDTA*

(up by 32.1% Y-o-Y)

115.7

Domestic & Export

(share in revenue)

18.5% & 81.5%

181.8

Revenue from Operations

(up 41.3% Y-o-Y)

21.9

PAT

(up by 74.4% Y-o-Y)

EBIDTA*

(up by 37.9% Y-o-Y)

30.5

Domestic & Export

(share in revenue)

27.5% & 72.5%

Q4 FY25FY25

*EBITDA: includes other income

----------------Page (3) Break----------------

s a n j i v a n i . c o . i n

MARKET OVERVIEW

----------------Page (4) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Global Medicine Market

5

Country Name/Year2018201920202021202220232024E2025E2026E2027E2028ECAGR %2024-2028

Asia-Pacific4514614775075475385595805986186373.4%

Latin America3423574384474484614734844894965061.9%

Western Europe4354454444484694634704764814854881.1%

India3543593704003903994124284434584743.5%

Africa & Middle East3853953934284254104134244344424511.9%

Eastern Europe3323393413583693623703773843883911.6%

China2552792713013083083233373493593693.7%

North America2702722702812902902942993033063091.3%

Japan1411431411451471481491511521521530.6%

Total2,9643,0493,1443,3163,3943,3783,4653,5563,6333,7043,778

Use of medicines region wise, Defined Daily Doses (DDD)

Source: IQVIA Institute, Dec 2023.

----------------Page (5) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Global Medicine Market

6

414

814

20182028

Defined Daily Doses

(DDD) in billions

14%

28%

20182028

Global use of

medicines

35%

73%

20182028

Global spending

on medicine

Source: IQVIA Institute, Dec2023.

----------------Page (6) Break----------------

s a n j i v a n i . c o . i n

ABOUT THE COMPANY

----------------Page (7) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

About Us

8

Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and four manufacturing plants at Navi Mumbai, Dehradun, Pimpri &

Czech Republic, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas

encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

4

Manufacturing

Facilities

84 million

Annual Ampoules

Capacity

12 million

Annual Liquid

injectables Capacity

48 million

Annual Vial

Capacity

120 million

Annual B Lactam

Tablet Capacity

180 million

Annual B Lactam

Capsule Capacity

72 million

Annual Capsule

Capacity

WHO-GMP/

DIGEMID / DDA

Certified

Plants

25

Countries

Geographical

Reach

~80%

Exports

Revenue

25+ years

Experience

720

million

Annual Tablet

Capacity

----------------Page (8) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Significant Milestone of Sanjivani

9

1.Navi Mumbai Plant

2.Listing no BSE April’96

Dehradun Plant

Achieved milestone of adding

100th product in the portfolio

1.Entered into a JV with Alevia Healthcare

S.R.O in Prague in May 23

2.Entered into a JV with Hindustan Antibiotics

Ltd in August 23

Year is mentioned as calendar year

2022

2009

1996

2023

1.Initial commercial

batches started in

Prague

2.Pune plant validation

batches started

2025

----------------Page (9) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Vision of the Company

10

To be one of India’s best research-based pharmaceutical companies, through focus on quality

and customer satisfaction.

To bring forth a new paradigm of products & services which lead to unprecedented growth for

our stakeholders, customers, strategic partners & team members. To grow the company on the

foundation of Passion, Performance & Partnership.

VISION

1. Quality

Products that we are proud of.

2. Customer Satisfaction

Ensuring customer delight.

VALUES

Creating a world-class organization offering

products, services & paradigms that open

up new worlds of opportunities.

MISSION

3. Growth for all stakeholders

Exceeding stakeholders expectations is our success-mantra.

4. Professionalism

People you love to work with. A culture of innovative thinking, backed by disciplined execution.

----------------Page (10) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Sanjivani Competitive Advantage

11

We have a compact and highly adaptable presence in

India, allowing us to be exceptionally nimble and agile

Rapid decision making capabilities

As pioneers in injectable manufacturing in India, we have

navigated the industry’s regulatory evolution from its early,

less stringent days. This experience allows us to effortlessly

adapt to current standards

Our long-standing experience in injectable manufacturing has

equipped us with a comprehensive understanding of diverse

production processes, allowing us to consistently optimize for

efficiency.

Our long standing presence in the industry has

established us as a respected leader, making us a

preferred partner for top talent and reputable suppliers

----------------Page (11) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Experienced Management

12

Mr. Ashwani Khemka

Chairman & Managing Director

Mrs. Mrunmai Sarvankar

Director

Mr. Srivardhan Khemka

Executive Director

Ms. Monika A. Singhania

Independent Director

Mr. Pritesh Jain

Chief Financial Officer

Mr. Abhay Shah

Independent Director

----------------Page (12) Break----------------

s a n j i v a n i . c o . i n

MANUFACTURING PLANT

----------------Page (13) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Manufacturing Plant – Alevia HealthCare, Czech Republic, Plant

14

----------------Page (14) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

IV Manufacturing Plant – SPL Infusion Private Limited, Pune Plant

15

----------------Page (15) Break----------------

s a n j i v a n i . c o . i n

CDMO KEY CLIENTS

----------------Page (16) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

CDMO Key Clients

17

Injectables

Oral & Nutraceuticals

----------------Page (17) Break----------------

s a n j i v a n i . c o . i n

COMPANY’S SEGMENT &

REVENUE MIX

----------------Page (18) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Product Category Mix (%)

19

71.9%

27.0%

1.0%

Injectables

Tablets

Nutraceuticals63.0%

33.4%

3.6%

Injectables

Tablets

Nutraceuticals

Q4 FY24

69.3%

29.1%

1.7%

Injectables

Tablets

Nutraceuticals

Q4 FY25

FY25FY24

58.7%37.1%

4.2%

Injectables

Tablets

Nutraceuticals

----------------Page (19) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

30.0%

70.0%

Domestic

Exports

Geographical Mix (%)

20

27.5%

72.5%

Domestic

Exports

Q4 FY25Q4 FY24

18.5%

81.5%

Domestic

Exports

24.9%

75.1%

Domestic

Exports

FY25FY24

----------------Page (20) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Region-wise Mix (%)

21

30.1%

33.6%

33.1%

3.1%

Latin America

Middle East & Africa

India & Subcontinent

CIS Countries

31.1%

34.9%

31.3%

2.8%

Latin America

Middle East & Africa

India & Subcontinent

CIS Countries

26.6%

46.1%

26.0%

1.3%

Latin America

Middle East & Africa

India & Subcontinent

CIS Countries

28.7%

34.4%

30.1%

6.9%

Latin America

Middle East & Africa

India & Subcontinent

CIS Countries

FY25

Q4 FY25Q4 FY24

FY24

----------------Page (21) Break----------------

s a n j i v a n i . c o . i n

GLOBAL FOOTPRINT

----------------Page (22) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Navi Mumbai

Global Footprint

23

Pimpri, Pune

Central

America

Prague

Latin

America

CIS Countries

India

Navi Mumbai, Dehradun, Pimpri & Prague

Dehradun

----------------Page (23) Break----------------

s a n j i v a n i . c o . i n

PRODUCT PORTFOLIO

----------------Page (24) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Product Portfolio

25

----------------Page (25) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Product Portfolio

26

UrologicsAnesthetics

Anti

Fungal

Anti

Convulsants

Anti Thyroid

Agent

Anesthetics

Anti

Emetics

Anti

Histamines

Anti

Diabetic

Anti

Depressants

Anti

Hypertensive Agent

Vitamin

Supplement

Anti-spasmodic

Anti-lepemic

Agent

Anti

Fibrinolytics

Anti-bacterialsSkeletal

Muscle Relaxant

Analgesic &

Anti Histaminic

----------------Page (26) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Product Portfolio

27

Non-opioid

Analgesics

AntisepticsNsaidsCorticosteroidsAntacids

Anti AnxietyNarcoticImmunosupress

ants

DiureticsHormoneTopical

Corticosteroids

AntipsychoticAnti ViralAntibioticNarcoticsAnti- Muscle

Relaxant

----------------Page (27) Break----------------

s a n j i v a n i . c o . i n

FINANCIALS

----------------Page (28) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Segment-wise Revenue

29

(Injectables, Oral & Nutraceuticals)

81.1

129.2130.8

Q4FY24Q3FY25Q4FY25

42.9

34.1

49.1

Q4FY24Q3FY25Q4FY25

4.6

10.2

1.9

Q4FY24Q3FY25Q4FY25

INJECTABLESORALS

NUTRACEUTICALS

Rs. In Mn.

----------------Page (29) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Quarterly Financials -

30

Revenue, EBITDA & Margin, PAT & Margin

Rs. In Mn.

129

164181174182

Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25

2224322931

17.2%

14.7%

17.9%

16.5%16.8%

Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25

REVENUE*EBIDTA** & EBIDTA Margin

1923292527

14.6%

13.8%

15.7%

14.2%

14.3%

Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25

PBT & PBT MarginPAT & PAT Margin

13

17

23

19

22

9.7%10.4%12.4%10.7%11.8%

Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25

PATPAT Margin %

*Revenue: operating revenue excluding other income **EBITDA: includes other income

----------------Page (30) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Q4 & FY25 Profit & Loss Statement

31

Particulars (Rs. In Mn.)Q4 FY25Q4 FY24YoY%Q3 FY25QoQ%FY25FY24YoY%

Revenue From Operations 181.8128.641.3%173.54.8%701.0544.128.8%

Other Income4.30.5713.0%3.136.9%12.15.2134.6%

Total Income186.1129.244.1%176.65.4%713.1549.329.8%

COGS93.949.589.8%99.3-5.4%404.8284.842.1%

Gross Profit92.1 79.715.7%77.319.2%308.3264.416.6%

Gross Margin (%)50.7%61.9%-1125bps44.6%611bps44.0%48.6%-462bps

Employee Benefit Exp.21.111.385.8%16.525.9%64.941.058.5%

Other Expenses40.646.2-12.2%32.227.0%127.6135.9-6.1%

EBITDA incl. other income30.5 22.137.9%28.66.5%115.787.632.1%

EBITDA Margin (%)16.8%17.2%-42bps16.5%26bps16.5%16.1%41bps

Depreciation1.82.4-22.6%1.615.7%6.29.3-33.5%

Finance Cost2.00.9129.1%1.94.4%5.92.5133.8%

PBT26.618.841.2%25.16.1%103.675.736.8%

Tax4.76.3-25.4%6.1-23.5%22.614.1 60.6%

PAT21.9 12.674.4%19.015.55%81.061.731.4%

PAT Margin (%)11.8%9.7%205bps10.7%104bps11.4%11.2%14bps

EPS (in Rs.)1.841.0870.4%1.6213.6%6.895.2830.5%

----------------Page (31) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Standalone Balance Sheet as on 31st March 2025

Particulars (Rs. In Mn.)Mar-25Mar-24

Equities & Liabilities

Equity Share Capital118.8116.8

Other Equity261.2162.1

Total Shareholder's Funds380.0279.0

Non-Current Liabilities

Long-term Borrowings52.99.7

Other Financial Liabilities7.73.5

Other Long-term Liabilities4.84.0

Total of Non-Current liabilities65.317.3

Current Liabilities

Short Term Borrowings3.40.0

Trade Payables152.5 57.4

Other Short-Term Liabilities33.369.5

Short Term Provisions15.410.2

Other Current Liabilities0.7

Total Current Liabilities204.6137.8

Total Liabilities650.0434.1

Particulars (Rs. In Mn.)Mar-25Mar-24

Assets

Non-Current Assets

Property, Plant & Equipment205.699.4

Other Intangible Assets0.00.0

Non-Current Financial Assets

Non-Current Investments

Investments30.0-

Trade Receivable6.32.9

Long Terms Loans & Advances14.936.2

Other Non-Current Assets12.19.2

Total Non-CurrentFinancial Assets63.348.2

Total – Non-Current Assets268.9147.7

Current Assets

Inventories104.297.3

Current Financial Assets

Trade Receivables166.847.0

Cash & Cash Equivalents6.35.4

Bank Balance other than Cash & Cash equivalent9.390.2

Short Term Loans & Advances86.837.6

Other Current Assets7.78.9

Total Current Financial Assets 276.9189.1

Total Current Assets381.0286.4

Total Assets650.0434.1

32

----------------Page (32) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Yearly Financials

33

306355

544

701

FY22FY23FY24FY25

REVENUE*

48456281

15.7%

12.5%

11.2%11.4%

FY22FY23FY24FY25

PAT & PAT Margin

4.94.55.3

6.9

FY22FY23FY24FY25

EPS In Rs.

Revenue, EBITDA & Margin, PAT & Margin

Rs. In Mn.

*Revenue: operating revenue excluding other income **EBITDA: includes other income

606288116

19.5%17.4%

16.1%16.5%

FY22FY23FY24FY25

EBIDTA** & EBIDTA Margin

----------------Page (33) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Yearly Financials

-0.8

0.3

2.4

3.2

FY22FY23FY24FY25

BOOK VALUE per share, Rs

339

270

74

138

FY22FY23FY24FY25

PAYABLES DAYS

1520

32

87

FY22FY23FY24FY25

RECEIVABLES DAYS

52

105

125

94

FY22FY23FY24FY25

INVENTORY DAYS

34

Inventory & Payable days calculated on COGS basis; Receivables days on sales basis

-229

-144

83

43

FY22FY23FY24FY25

CASH CONVERSION CYCLE DAYS

----------------Page (34) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Long Term Growth Drivers

35

Expand Product

Portfolio

Expand into

New Geographies

Therapeutic

Diversification

Strategic partnerships

& Collaborations

1

2

4

3

----------------Page (35) Break----------------

www.sanjivani.co.inInvestor Presentation Q4 & FY25

Stock Information

36

Shareholding Pattern as on 31st March 2025

28.9

6.2

18.2

8.2

38.6

PromoterInstitutionsHNICorporate BodiesRetail

0

50

100

150

200

250

300

Apr-24May-24Jun-24Jul-24Aug-24Sep-24Oct-24Nov-24Dec-24Jan-25Feb-25Mar-25

BSE HealthcareSanjivani Share Price

Stock Information (as on 31st March 2025)

Market Cap. (in crores)285

Stock Price239.7

52 Week (High / Low)388.5 / 143.9

BSE – Symbol531569

Free Float (No. of Shares)84,51,239

Average Daily Volume (3months) - BSE11.1k

----------------Page (36) Break----------------

THANK YOU

Jill Chandrani

+91 7506023955

Email: jill@s-ancial.com

215, Shivshakti Industrial Estate,

J.R Boricha Marg, Lower Parel (E) Mumbai - 400011

Sanjivani Paranteral Limited

205, P.N.Kothari Industrial Estate, L.B.S.

Marg Bhandup (W), Mumbai- 400078, India.

Ph: +91-22-20812600 / 25620515

Email:corporate@sanjivani.co.in

----------------Page (37) Break----------------